Loading
Amneal Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Dec 2021.
Amneal Pharmaceuticals, Inc.: what insiders have been doing
This page follows insider dealings at Amneal Pharmaceuticals, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Bridgewater Township, United States. The last twelve months, up to 18 October 2026, brought 26 filings signed by 16 insiders.
All open-market trades in the period are sales: 6 sales worth €7.1M, by 5 insiders, with no purchase on record. The largest single trade was a sale of €3.2M by Daly Jason B., published on 13 August 2026, equal to 0.052% of the market capitalisation.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (5,458 companies, median 22 filings), a count of 26 filings is above the norm. Since 2021, the database holds 3 purchases and 40 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 3.02 bn USD and net income of 72.1 m USD.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
162
Thresholds
n/a
Buy Volume
€919,210
3 ops. · all time
Sell Volume
€67M
40 ops. · all time
Who traded when
BuySaleGautam Patel9 sales
Jason B. Daly6 sales
Nikita Shah5 sales
John Kiely4 sales
Andrew S. Boyer2 sales
Deborah M. Autor2 sales
+4 other insiders
Since the insiders bought
- -52.7%Entry US$4.67 · Close at T+365 US$2.21
- -52.6%Entry US$4.56 · Close at T+365 US$2.16
- -52.6%Entry US$4.56 · Close at T+365 US$2.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Amneal Pharmaceuticals, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$22.71.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,118 of 24,148 companies
40.7
score / 100
Value43
Quality38
FCF yld3.4%
Earn yld1.1%
EV/EBITDA15.6x
ROE·
Gross mgn37%
Net mgn2.4%
Debt/EBITDA4.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$19.25
Analyst consensus
7 analystsStrong buy
US$20.00Target US$22.71(+18%)US$27.00
Income statement
RevenueUS$3B
Gross profitUS$1.1B37% margin
EBITDAUS$603.9M20% margin
Net incomeUS$72.1M5.0% margin
Valuation
PER (trailing)39.3x
PER (forward)16.1x
P/Book186.9x
Beta1.22
Balance sheet & cash
Market capUS$6.7B
Total debtUS$2.7B
Free Cash FlowUS$225.6M
Debt / Equity2387%
Profitability & ownership
ROE613.0%
ROA8.6%
% insiders52.1%
% institutions48.7%
Last declaration on 21 September 2026
Declarations162 total
20,445 shares0Class A Common StockSEC:0001628280-26-062915:0
20,445 shares@ US$14.450.0042% mcap4.8% of flowClass A Common StockSEC:0001628280-26-061836:0
152,426 shares0Class A Common StockSEC:0001628280-26-058918:0
10,000 shares0Class A Common StockSEC:0001628280-26-057147:1
50,000 shares@ US$17.640.013% mcap47.0% of flowClass A Common StockSEC:0001628280-26-057147:0
50,000 shares@ US$17.59430.053% mcap100.0% of flowCOMMON STOCKSEC144:0001628280-26-056733
6,613 shares@ US$17.700.0017% mcap2.4% of flowClass A Common StockSEC:0001628280-26-056754:0
210,000 shares@ US$17.400.052% mcap74.0% of flowClass A Common StockSEC:0001628280-26-056754:1
146,403 shares@ US$17.510.037% mcap41.9% of flowClass A Common StockSEC:0001628280-26-056757:0
168,573 shares@ US$17.180.041% mcap47.4% of flowClass A Common StockSEC:0001628280-26-056752:0
210,000 shares@ US$17.36330.22% mcap100.0% of flowCOMMON STOCKSEC144:0001628280-26-056196
146,403 shares@ US$17.46530.15% mcap100.0% of flowCOMMON STOCKSEC144:0001628280-26-056220
283,632 sharesClass A Common StockSEC:0001628280-26-056288:0
12,763,469 sharesClass A Common StockSEC:0000898432-26-000655:0
6,381,734 sharesClass A Common StockSEC:0001628280-26-056285:0
6,381,734 sharesClass A Common StockSEC:0001628280-26-056297:0
168,573 shares@ US$17.310.042% mcap47.8% of flowCommonSEC144:0001949846-26-000494
34,819 shares@ US$12.940.0070% mcap72.6% of flowClass A Common StockSEC:0001628280-26-034106:0
59,931 sharesClass A Common StockSEC:0001628280-26-015283:0
59,931 sharesClass A Common StockSEC:0001628280-26-015285:0
22,645 sharesClass A Common StockSEC:0001628280-26-015241:0
45,290 sharesClass A Common StockSEC:0001628280-26-015239:0
39,252 sharesClass A Common StockSEC:0001628280-26-015238:0
36,232 sharesClass A Common StockSEC:0001628280-26-015235:0
50,000 shares@ US$11.72100.0% of flowClass A Common StockSEC:0001628280-25-053188:0
25 of 162 declarations
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States, with headquarters in Bridgewater, New Jersey, United States. The company was founded in 2002 by brothers Chirag and Chintu Patel around a clear mission: improve access to essential medicines by offering high-quality treatments at affordable prices. Over time, Amneal has evolved from a generics-focused business into a more diversified pharmaceutical platform spanning affordable medicines, specialty pharmaceuticals and distribution services. ([investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Unveils-Bold-New-Brand-to-Reimagine-Whats-Possible-in-Making-Medicine-Accessible-for-All-2026-PkNbhmgDo5/default.aspx?utm_source=openai))
Today, Amneal reports three business segments: Affordable Medicines, Specialty and AvKARE. Affordable Medicines includes retail generics, sterile injectables, biosimilars and certain international revenues. This segment covers a broad portfolio across dosage forms and delivery systems, including more complex products that face higher technical and regulatory barriers than commoditized generics. The Specialty segment is centered mainly on central nervous system and endocrine disorders. AvKARE provides pharmaceuticals, medical and surgical products and services, primarily to U.S. government agencies and institutional customers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000012/R35.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Amneal’s differentiation lies in its ability to participate across multiple parts of the pharmaceutical value chain. It competes in high-volume generics, but also in more technically demanding injectables, biosimilars and branded specialty therapies. The company also highlights a sizable U.S. manufacturing and R&D footprint, which supports supply-chain resilience, domestic production capabilities and regulatory execution. Recent company materials describe Amneal as one of the leading U.S.-based companies in the generics market by prescriptions, underscoring its scale in affordable medicines. ([amneal.com](https://amneal.com/making-medicines-more-accessible-right-here-in-america/?utm_source=openai))
Key products have become increasingly important to the investment case. CREXONT, an extended-release carbidopa/levodopa product for Parkinson’s disease, received FDA approval in 2024 and began commercialization the same year, strengthening Amneal’s Specialty franchise. In 2025, the company also secured FDA approval for Brekiya, described as the first and only ready-to-use dihydroergotamine autoinjector for adult migraine with or without aura and cluster headaches, and launched it commercially in October 2025. These launches point to a gradual mix shift toward more differentiated, higher-value products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1723128/000172312824000032/amrx-20240630.htm?utm_source=openai))
Recent developments have been constructive. Amneal said all three segments posted double-digit revenue growth in 2024 in results released in early 2025; Brekiya was approved by the FDA in May 2025; the company announced a refinancing of its existing credit agreement in July 2025; it reported positive interim Phase 4 data for CREXONT in December 2025; and in January 2026 it unveiled a refreshed brand identity to reflect its transition into a diversified global biopharmaceutical leader. ([investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
